Combined, these results suggest that activation of both subtypes with a β2-β3-AR dual agonist would effectively combat obesity and its related metabolic perturbations, while largely limiting cardiovascular side-effects by avoiding β1-AR stimulation. This evidence concerns the gene ADRB3 and obesity disorder.